NEW YORK, Aug. 22 – Gilead Sciences is selling its 49 percent interest in oligonucleotides manufacturer Proligo to Degussa Corporation, which currently holds the remaining Proligo shares, the company announced on Wednesday.

The deal, expected to close on Aug. 31, is for $14 million in cash, according to Foster City, Calif.-based Gilead.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.